CERC Share Price | Avalo Therapeutics, Inc. Stock Analysis & Recommendation

Q: Is Avalo Therapeutics, Inc. overvalued or undervalued?

As of 8 July 2024, Avalo Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. Given the current metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 0.36, an EV to EBIT of 1.55, and an EV to EBITDA of 1.56, which suggest that the company is not generating sufficient value relative to its market price.In comparison to peers, Avalo's valuation ratios are significantly lower, with 180 Life Sciences Corp. showing an EV to EBITDA of -61.84 and ABVC BioPharma, Inc. at -23.18, indicating that Avalo is not alone in facing valuation challenges within its sector. Despite recent stock performance showing a 59.89% year-to-date return compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a staggering -99.85% return over the past five years.

Q: Is Avalo Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Avalo Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The monthly MACD and KST are mildly bullish, indicating some strength in the longer term. In terms of performance, Avalo has outperformed the S&P 500 significantly over the past week (9.19% vs. 1.05%) and month (31.13% vs. 2.33%), while the year-to-date return of 59.89% also surpasses the S&P's 12.22%. However, the longer-term returns over 3 years and 5 years show substantial declines compared to the S&P 500. Overall, the current technical indicators suggest a strong bullish sentiment in the short to medium term.

Q: How big is Avalo Therapeutics, Inc.?

Market Cap: As of Jun 18, Avalo Therapeutics, Inc. has a market capitalization of 48.40 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Avalo Therapeutics, Inc. reported net sales of 0.44 million and a net profit of 73.01 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 133.03 million and total assets of 150.73 million.

Q: What does Avalo Therapeutics, Inc. do?

Overview: Avalo Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for pediatric and orphan diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Net Profit: -13 Million (Quarterly Results - Mar 2025) Market Cap: USD 48.40 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -37.56% Price to Book: 0.39Contact Details: Address: 540 Gaither Rd Ste 400, ROCKVILLE MD: 20850-6713 Tel: 1 410 5228707 Fax: 1 302 6365454 Website: http://www.cerecor.com

Q: Who are in the management team of Avalo Therapeutics, Inc.?

As of March 2022, the management team of Avalo Therapeutics, Inc. includes Dr. Sol Barer as the Chairman of the Board, Mr. Michael Cola as the Chief Executive Officer and Director, and Dr. Suzanne Bruhn, Mr. Joseph Miller, Mr. Steven Boyd, Mr. Phil Gutry, and Dr. Gilla Kaplan as Directors, with the latter three serving as Independent Directors.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.37 M

Shareholding (Mar 2026)

FII

9.16%

Held by 26 FIIs

DII

82.76%

Held by 11 DIIs

Promoter

8.09%

Is Avalo Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Avalo Therapeutics, Inc. is considered overvalued with key ratios indicating insufficient value generation, despite a strong year-to-date stock performance, and a concerning long-term return of -99.85%.

View full answer

Is Avalo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Avalo Therapeutics, Inc. shows a strong bullish trend supported by positive technical indicators, significantly outperforming the S&P 500 in the short term, despite longer-term declines.

View full answer

How big is Avalo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Avalo Therapeutics, Inc. has a market capitalization of 48.40 million, with net sales of 0.44 million and a net profit of 73.01 million over the latest four quarters. The company reported shareholder's funds of 133.03 million and total assets of 150.73 million as of Dec 24.

View full answer

What does Avalo Therapeutics, Inc. do?

22-Jun-2025

Avalo Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pediatric and orphan diseases. As of March 2025, it has a market cap of $48.40 million and reported a net profit loss of $13 million.

View full answer

Who are in the management team of Avalo Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Avalo Therapeutics, Inc.'s management team includes Dr. Sol Barer (Chairman), Mr. Michael Cola (CEO and Director), and Directors Dr. Suzanne Bruhn, Mr. Joseph Miller, Mr. Steven Boyd, Mr. Phil Gutry, and Dr. Gilla Kaplan, with Boyd, Gutry, and Kaplan serving as Independent Directors.

View full answer

Compare Avalo Therapeutics, Inc. with Similar Stocks

Baudax Bio, Inc.Adial Pharmaceuticals, Inc.Dermata Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 317 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.16

Return on Equity

-82.77%

Price to Book

3.81

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.14%

6 Months

-22.26%

1 Year

208.82%

2 Years

24.58%

3 Years

275.0%

4 Years

-98.98%

5 Years

-99.86%

Avalo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-61.06%

EBIT Growth (5y)

-14.47%

EBIT to Interest (avg)

-31.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

-0.01

Tax Ratio

0.16%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

89.45%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.81

EV to EBIT

-3.02

EV to EBITDA

-3.04

EV to Capital Employed

-17.05

EV to Sales

220.55

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-82.77%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 9 Schemes (9.11%)

Foreign Institutions

Held by 26 Foreign Institutions (9.16%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -100.00% vs 0.00% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -43.07% vs 55.23% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.90",
          "val2": "-19.70",
          "chgp": "-6.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "5.20",
          "chgp": "-90.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.60",
          "val2": "-13.70",
          "chgp": "-43.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-334,610.20%",
          "chgp": "33,461.02%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -75.00% vs -78.95% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -123.08% vs -11.43% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-72.60",
          "val2": "-40.70",
          "chgp": "-78.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.50",
          "val2": "2.50",
          "chgp": "-480.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-78.30",
          "val2": "-35.10",
          "chgp": "-123.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,236,016.90%",
          "val2": "-92,678.00%",
          "chgp": "-1,14,333.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-20.90

-19.70

-6.09%

Interest

0.00

Exceptional Items

0.50

5.20

-90.38%

Consolidate Net Profit

-19.60

-13.70

-43.07%

Operating Profit Margin (Excl OI)

0.00%

-334,610.20%

33,461.02%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -100.00% vs 0.00% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -43.07% vs 55.23% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.10

0.40

-75.00%

Operating Profit (PBDIT) excl Other Income

-72.60

-40.70

-78.38%

Interest

0.00

Exceptional Items

-9.50

2.50

-480.00%

Consolidate Net Profit

-78.30

-35.10

-123.08%

Operating Profit Margin (Excl OI)

-1,236,016.90%

-92,678.00%

-1,14,333.89%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -75.00% vs -78.95% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -123.08% vs -11.43% in Dec 2024

All Annual Results

Company CV

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Company Coordinates

Company Details

540 Gaither Rd Ste 400 , ROCKVILLE MD : 20850-6713

Tel: 1 410 5228707

http://www.cerecor.com

Registrar Details